185 related articles for article (PubMed ID: 24063843)
21. Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI.
Brener SJ; Dambrink JH; Maehara A; Chowdhary S; Gershlick AH; Genereux P; Koolen J; Mehran R; Fahy M; Gibson CM; Stone GW
EuroIntervention; 2014 Feb; 9(10):1195-201. PubMed ID: 24561570
[TBL] [Abstract][Full Text] [Related]
22. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Estévez-Loureiro R; Salgado-Fernández J; Marzoa-Rivas R; Barge-Caballero E; Pérez-Pérez A; Noriega-Concepción V; Calviño-Santos R; Vázquez-Rodríguez JM; Vázquez-González N; Castro-Beiras A; Kaski JC
Thromb Res; 2009 Nov; 124(5):536-40. PubMed ID: 19467699
[TBL] [Abstract][Full Text] [Related]
23. Effects of baseline coronary occlusion and diabetes mellitus in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Piccolo R; Galasso G; Iversen AZ; Eitel I; Dominguez-Rodriguez A; Gu YL; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Trimarco B; Thiele H; Piscione F
Am J Cardiol; 2014 Oct; 114(8):1145-50. PubMed ID: 25193670
[TBL] [Abstract][Full Text] [Related]
24. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
Ibanez B; Macaya C; Sánchez-Brunete V; Pizarro G; Fernández-Friera L; Mateos A; Fernández-Ortiz A; García-Ruiz JM; García-Álvarez A; Iñiguez A; Jiménez-Borreguero J; López-Romero P; Fernández-Jiménez R; Goicolea J; Ruiz-Mateos B; Bastante T; Arias M; Iglesias-Vázquez JA; Rodriguez MD; Escalera N; Acebal C; Cabrera JA; Valenciano J; Pérez de Prado A; Fernández-Campos MJ; Casado I; García-Rubira JC; García-Prieto J; Sanz-Rosa D; Cuellas C; Hernández-Antolín R; Albarrán A; Fernández-Vázquez F; de la Torre-Hernández JM; Pocock S; Sanz G; Fuster V
Circulation; 2013 Oct; 128(14):1495-503. PubMed ID: 24002794
[TBL] [Abstract][Full Text] [Related]
25. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
[TBL] [Abstract][Full Text] [Related]
26. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
[TBL] [Abstract][Full Text] [Related]
27. Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial).
Palmerini T; Généreux P; Mehran R; Dangas G; Caixeta A; Riva DD; Mariani A; Xu K; Stone GW
Am J Cardiol; 2013 May; 111(9):1237-45. PubMed ID: 23411106
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the X-SIZER thrombectomy device with adjunct abciximab during primary angioplasty and stenting for ST-segment elevation myocardial infarction.
Low AF; Lim YT; Teo SG; Budiono B; Sutandar A; Tan HC
J Interv Cardiol; 2005 Aug; 18(4):267-73. PubMed ID: 16115156
[TBL] [Abstract][Full Text] [Related]
29. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
[TBL] [Abstract][Full Text] [Related]
30. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
Maioli M; Bellandi F; Leoncini M; Toso A; Dabizzi RP
J Am Coll Cardiol; 2007 Apr; 49(14):1517-24. PubMed ID: 17418289
[TBL] [Abstract][Full Text] [Related]
31. Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial.
Dizon JM; Brener SJ; Maehara A; Witzenbichler B; Biviano A; Godlewski J; Parise H; Dambrink JH; Mehran R; Gibson CM; Stone GW
Eur Heart J Acute Cardiovasc Care; 2014 Mar; 3(1):78-83. PubMed ID: 24562806
[TBL] [Abstract][Full Text] [Related]
32. Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: results from the INFUSE-AMI study.
Sanidas EA; Brener SJ; Maehara A; Généreux P; Witzenbichler B; El-Omar M; Fahy M; Mehran R; Gibson CM; Stone GW
Catheter Cardiovasc Interv; 2014 Apr; 83(5):704-10. PubMed ID: 24030863
[TBL] [Abstract][Full Text] [Related]
33. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction.
Stone GW; Martin JL; de Boer MJ; Margheri M; Bramucci E; Blankenship JC; Metzger DC; Gibbons RJ; Lindsay BS; Weiner BH; Lansky AJ; Krucoff MW; Fahy M; Boscardin WJ;
Circ Cardiovasc Interv; 2009 Oct; 2(5):366-75. PubMed ID: 20031745
[TBL] [Abstract][Full Text] [Related]
34. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
[TBL] [Abstract][Full Text] [Related]
35. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
[TBL] [Abstract][Full Text] [Related]
36. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Iversen A; Abildgaard U; Galloe A; Hansen PR; Galatius S; Madsen JK; Engstroem T; Pedersen S; Jensen KS; Jensen JS
J Interv Cardiol; 2011 Apr; 24(2):105-11. PubMed ID: 21175845
[TBL] [Abstract][Full Text] [Related]
37. Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry).
Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Janzon M; Mielecki W; Zmudka K; Dubiel JS; Dudek D
Kardiol Pol; 2012; 70(3):215-21. PubMed ID: 22430397
[TBL] [Abstract][Full Text] [Related]
38. ST-segment analysis to predict infarct size and functional outcome in acute myocardial infarction treated with primary coronary intervention and adjunctive abciximab therapy.
Sciagrà R; Parodi G; Migliorini A; Valenti R; Antoniucci D; Sotgia B; Pupi A
Am J Cardiol; 2006 Jan; 97(1):48-54. PubMed ID: 16377283
[TBL] [Abstract][Full Text] [Related]
39. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Eitel I; Desch S; Schindler K; Fuernau G; Schuler G; Thiele H
Int J Cardiol; 2011 Nov; 153(1):21-5. PubMed ID: 20817283
[TBL] [Abstract][Full Text] [Related]
40. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
Nikolsky E; Aymong ED; Halkin A; Grines CL; Cox DA; Garcia E; Mehran R; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Cohen DA; Negoita M; Lansky AJ; Stone GW
J Am Coll Cardiol; 2004 Aug; 44(3):547-53. PubMed ID: 15358018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
